We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
DiaKine Therapeutics and Kinexum Metabolics to Develop Combination Treatment to Type 1 Diabetes
News

DiaKine Therapeutics and Kinexum Metabolics to Develop Combination Treatment to Type 1 Diabetes

DiaKine Therapeutics and Kinexum Metabolics to Develop Combination Treatment to Type 1 Diabetes
News

DiaKine Therapeutics and Kinexum Metabolics to Develop Combination Treatment to Type 1 Diabetes

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "DiaKine Therapeutics and Kinexum Metabolics to Develop Combination Treatment to Type 1 Diabetes"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

DiaKine Therapeutics, Inc. and Kinexum Metabolics, Inc. have announced an agreement to jointly develop a new combination therapy that has shown, in preclinical studies, to cause type 1 diabetes to go into remission by protecting and promoting the growth of new insulin-producing cells.

A Phase 2 human clinical trial with the new combination therapy, consisting of DiaKine’s Lisofylline (LSF) and Kinexum’s INGAP peptide, is expected to begin in late 2008. The trial will be unique in that patients who are beyond the ‘newly diagnosed’ period will be included in the study. Current trials seeking to treat people with type 1 diabetes do not include those with established disease.

“We believe these two drugs in combination create a unique and highly-effective treatment that could restore endogenous insulin to people with type 1 diabetes,” said Dr. Jerry Nadler, Chief Scientific Office for DiaKine Therapeutics. “It is becoming abundantly clear that a combination therapy is the best path for restoring the body’s natural ability to regulate blood sugar and giving people with type 1 diabetes their lives back.”

“Pursuing a cure for type 1 diabetes remains the strongest interest and commitment in my career. I see great promise in this scientific and corporate collaboration for achieving a definitive treatment of this difficult disease,” said Alexander “Zan” Fleming, M.D., who headed diabetes drug review at FDA and now serves as Chief Medical Officer of Kinexum Metabolics.

“We believe that the combination therapy of Lisofylline and INGAP peptide has the potential to be a blockbuster drug,” said Keith D. Ignotz, President and CEO of DiaKine Therapeutics. “We believe that, if successful, this new therapy could dramatically change the approach to treating diabetes.” Kevin Roché, CEO of Kinexum Metabolics, added, “It is clear that we will not get to a cure for type 1 diabetes if we don’t use a combination of therapies. This collaboration is part of the plan for doing that sooner than later.”

Lisofylline is said to be a synthetic small molecule with novel anti-inflammatory properties. LSF has demonstrated that it can prevent Type-1 diabetes in preclinical models. LSF has shown to improve cellular mitochondrial function and to reduce interleukin 12 (IL-12) signaling and STAT-4 activation in target cells and tissues. IL-12 and STAT 4 activation are important pathways linked to inflammation and immune damage to insulin producing cells.

Islet neogenesis associated protein (INGAP) is a member of the Reg3 family of pancreatic proteins. INGAP peptide, the active portion of the larger protein, induces islet regeneration in multiple species including humans. It is currently under development by Kinexum Metabolics, Inc.

Advertisement